 Connection
James Burton to Hepacivirus
This is a "connection" page, showing publications James Burton has written about Hepacivirus.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.963 |
|
|
|
-
Burton JR, Rosen HR. Treatment of HCV recurrence: do the pretransplantation rules apply? Liver Transpl. 2006 Jul; 12(7):1044-8.
Score: 0.246
-
Terrault NA, Burton J, Ghobrial M, Verna E, Bayer J, Klein C, Victor D, Mohan S, Trotter J, Dodge J, Niemann CU, Rubin RA. Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors. Hepatology. 2021 06; 73(6):2110-2123.
Score: 0.169
-
Burton JR, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS, Everson GT, Rubin E, Wiesner R, Pomfret EA. Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. Transplantation. 2020 03; 104(3):476-481.
Score: 0.159
-
Burton JR, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol. 2014 Sep; 61(3):508-14.
Score: 0.106
-
Burton JR, Everson GT. HCV NS5B polymerase inhibitors. Clin Liver Dis. 2009 Aug; 13(3):453-65.
Score: 0.076
-
Smyk-Pearson S, Golden-Mason L, Klarquist J, Burton JR, Tester IA, Wang CC, Culbertson N, Vandenbark AA, Rosen HR. Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis. 2008 Jan 01; 197(1):46-57.
Score: 0.068
-
MacBrayne CE, Castillo-Mancilla J, Burton JR, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 01; 73(1):156-159.
Score: 0.034
-
O'Leary JG, Fontana RJ, Brown K, Burton JR, Firpi-Morell R, Muir A, O'Brien C, Rabinovitz M, Reddy R, Ryan R, Shprecher A, Villadiego S, Prabhakar A, Brown RS. Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. Transpl Int. 2017 Feb; 30(2):196-208.
Score: 0.032
-
Verna EC, Saxena V, Burton JR, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015 Aug; 99(8):1644-51.
Score: 0.029
-
Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18; 371(25):2375-82.
Score: 0.027
-
Golden-Mason L, Burton JR, Castelblanco N, Klarquist J, Benlloch S, Wang C, Rosen HR. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology. 2006 Nov; 44(5):1098-109.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|